to go to the previous page
Challenging Cases in the Management of Newly Diagnosed and Recurrent Prostate Cancer
Tuesday, November 3, 2009
Click the plus sign to see more detailed information
about each speaker.
Over the course of my career I have published 78 peer reviewed manuscripts on genito-urinary malignancies, 70 of these being on prostate cancer, and 51 as either first or co-principle author. My research interests have covered many aspects of prostate cancer, including the use of intermittent androgen suppression, the pathology of post radiation prostate biopsies, the use of neoadjuvant hormonal therapy combined with radiation therapy, post brachytherapy PSA kinetics, predictors of urinary sequelae after brachytherapy, critical organ dosimetry, and quality of life after both external beam radiotherapy and brachytherapy. I have been the principal investigator in multi-institutional trials run by NCIC, RTOG and ACOSOG.
Theodore DeWeese, Professor, Johns Hopkins University School of Medicine
Ian Thompson, Chair
, University of Texas Health Science Center San Antonio
Dr. Ian Thompson received his undergraduate degree from West Point and his M.D. degree from Tulane University. After a Residency in Urology in San Antonio, he completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He is Chairman of the Department of Urology at the University of Texas Health Science Center at San Antonio. Dr. Thompson has published over 360 scientific papers, several dozen book chapters, and has edited five textbooks in medicine and surgery. He currently serves as Chair the Residency Review Committee for Urology and Vice-Chair of the Early Detection Research Network of the National Cancer Institute. He previously served as the President of the Society of Urologic Oncology, the international association of physicians who conduct research and who provide care for patients with urologic malignancies. He has served as a Visiting Professor at most major academic institutions in the U.S. as well as at many leading cancer centers in Europe, Asia, Central and South America, as well as Australia.
Dr. Thompson is the Principal Investigator of the San Antonio Center for Biomarkers Of Risk of Prostate Cancer. This cohort study, with up to 8 years of followup, currently follows over 3,600 men for development of prostate cancer and has been the source of many recent important developments in the early detection of prostate cancer. He was the primary coordinator of the 18,882-subject Prostate Cancer Prevention Trial, is the Localized Prostate Organ Site Chair for the Southwest Oncology Group, and has been PI or a co-investigator in several large national clinical trials. The Prostate Cancer Prevention Trial, sponsored by the National Cancer Institute, was the largest prostate cancer study ever conducted for prevention of prostate cancer and demonstrated that the medication, finasteride, was associated with a lower risk of prostate cancer.
Anders Widmark, Professor, Umea University Hospital
Anthony D'Amico, Radiation Oncologist
, Brigham and Womens Hospital and Dana Farber Cancer
International Expert in detection, staging and management of prostate cancer
Audio Synchronized to PowerPoint